Paroxysmal Nocturnal hemoglobinuria (PNH) Registry
Study identifier:M07-001
ClinicalTrials.gov identifier:NCT01374360
EudraCT identifier:N/A
CTIS identifier:N/A
Recruiting
Official Title
Paroxysmal Nocturnal hemoglobinuria (PNH) Registry
Medical condition
paroxysmal nocturnal hemoglobinuria
Phase
Phase 4
Healthy volunteers
No
Study drug
-
Sex
All
Estimated Enrollment
5950
Study type
Observational
Age
n/a - n/a
Date
Study Start Date: 29 Oct 2004
Estimated Primary Completion Date: 31 Dec 2024
Estimated Study Completion Date: 31 Dec 2024
Study design
Allocation: Non-randomized
Endpoint Classification: -
Intervention Model: -
Masking: -
Primary Purpose: -
Verification:
Verified 01 Feb 2024 by Alexion Pharmaceuticals, Inc.
Sponsors
Alexion Pharmaceuticals, Inc.
Collaborators
-
Inclusion and exclusion criteria
Loading...
Sort by status
- All Statuses
- Recruiting
- Not yet recruiting
- Recruiting complete
- Completed
- Other
No locations available
| Arms | Assigned Interventions |
|---|---|
| Receiving Soliris or Ultomiris PNH patients of any age, including minors, that are receiving Soliris or Ultomiris | - |
| Not receiving Soliris or Ultomiris PNH patients of any age, including minors, that are not receiving Soliris or Ultomiris | - |
Contacts
Investigators
Principal Investigator
Phillipe Gustovic
Alexion Pharmaceuticals, Inc.
